ValiRx

ValiRx is a drug development company focused on translating scientific innovation into clinical candidates for cancer, related diseases, and women's health. Our specialized business model connects science, finance, and commerce to accelerate early-stage drug development. VAL201 is the company’s small molecule peptide, with its primary indication for prostate cancer and potential for further research and development in breast and ovarian cancers.